Over the years, the neurotherapeutic landscape in multiple sclerosis (MS) has evolved rapidly. New disease-modifying treatments have been developed with various novel mechanisms that demonstrate improved efficacy and safety. It is believed that a more tailored treatment approach would allow for better personalization of drug selection for patients. Sphingosine-1-phosphate (S1P) receptor modulators, one of the […]